Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor.

No abstract is available for this paper.

• Publication year

  1971

• Venue

  Journal of Neurological Sciences

• Publication date

  1971-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0022-510X(71)90178-XPMID 5125758
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Striatal bradykinesia alleviated by intracaudate injection ofl-dopa

  2005cited by this paper
• [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

  1998cited by this paper
• Spasticity and Rigidity

  1972cited by this paper
• Projections from the body of the caudate nucleus in the rhesus monkey.

  1970cited by this paper
• The rubro-olivo-cerebello-rubral loop and postural tremor in the monkey.

  1970cited by this paper
• Newer medical treatment in parkinsonism.

  1970cited by this paper
• L-Dopa-Induced Release of Cerebral Monoamines

  1970cited by this paper
• L-Dopa: Effect on Concentrations of Dopamine, Norepinephrine, and Serotonin in Brains of Mice

  1970cited by this paper
• Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

  1970cited by this paper
• L-Dopa: Effect of Concentrations of Dopamine, Norepinephrine, and Serotonin in Brains of Mice

  1970cited by this paper
• Treatment of parkinsonism with levodopa.

  1969cited by this paper
• Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra.

  1969cited by this paper
• Drug-induced Relief of the Tremor in Monkeys with Mesencephalic Lesions

  1969cited by this paper
• The effect of 5-hydroxytryptamine and 5-hydroxytryptophan on extra-pyramidal function.

  1969cited by this paper
• STUDIES OF AMINES IN THE STRIATUM IN MONKEYS WITH NIGRAL LESIONS

  1969cited by this paper
• The metabolism of orally administered l‐DOPA in Parkinsonism

  1969cited by this paper
• ASSOCIATION OF TYROSINE HYDROXYLASE WITH SYNAPTIC VESICLES IN BOVINE CAUDATE NUCLEUS 1

  1969cited by this paper
• Modification of Parkinsonism--chronic treatment with L-dopa.

  1969cited by this paper
• Activities of enzymes involved in the formation and destruction of biogenic amines in various areas of human brain.

  1969cited by this paper
• Athetoid and Choreiform Hyperkinesias Produced by Caudate Lesions in the Cat

  1969cited by this paper
• L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.

  1969cited by this paper
• The nigrostriatal pathway: a correlative study based on neuroanatomical and neurochemical criteria in the cat and the monkey.

  1969cited by this paper
• The effect of brain stem lesions on tyrosine and tryptophan hydroxylases in various structures of the telencephalon of the cat.

  1969cited by this paper
• Serotonin (5-HT) metabolism in Huntington's chorea

  1968cited by this paper
• A rapid and sensitive procedure for the combined assay of noradrenaline, dopamine AND SEROTONIN IN A SINGLE BRAIN SAMPLE.

  1968cited by this paper
• Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue.

  1968cited by this paper
• Physiologic and pharmacologic considerations of biogenic amines in the nervous system.

  1968cited by this paper
• Caudate Unit Responses to Nigral Stimuli: Evidence for a Possible Nigro-Neostriatal Pathway

  1968cited by this paper
• The combined use of alpha-methyltyrosine and threo-dihydroxyphenylserine--selective reduction of dopamine levels in the central nervous system.

  1968cited by this paper
• The combined use of α-methyltyrosine and threo-dihydroxyphenylserine—selective reduction of dopamine levels in the central nervous system

  1968cited by this paper
• Opposite effect of harmaline on seotonin and on dopamine and its metabolites, homovanillic acid and norepinephrine, in the brain of the cat.

  1968cited by this paper
• Studies on neuromelanin

  1967cited by this paper
• Activation of Tyrosine Hydroxylation in Rat Brain in vivo by Chlorpromazine

  1967cited by this paper
• Electrophysiological analysis of reciprocal caudato-nigral relations.

  1967cited by this paper
• A case of striatal hemiplegia.

  1967cited by this paper
• The action of dopamine on neurones of the caudate nucleus

  1967cited by this paper
• The Cerebellum as a Neuronal Machine

  1967cited by this paper
• The effect of neuroleptics on the activity of central catecholamine neurones.

  1967cited by this paper
• The efferent projections of the putamen in the monkey.

  1967cited by this paper
• Aromatic amino acids and modification of parkinsonism.

  1967cited by this paper
• Striatal and spinal lesions eliminating reserpine and physostigmine rigidity.

  1967cited by this paper
• Effect of monoamine oxidase inhibitors on the concentrations of dopamine and serotonin in the striatum of the cat with and without unilateral brainstem lesions.

  1967cited by this paper
• Accelerated synthesis of dopamine-C14 from tyrosine-C14 in rat brain after chlorpromazine.

  1967cited by this paper
• Cholinergic-anticholinergic antagonism in parkinsonism.

  1967cited by this paper
• The basal ganglia and posture.

  1967cited by this paper
• A cerebellar mechanism in resting tremor

  1966cited by this paper
• The effects of lesions in the substantia nigra.

  1966cited by this paper
• Site of action of dopamine and apomorphine on compulsive gnawing behaviour in rats

  1966cited by this paper
• Reciprocal Effects on α- and γ-Motoneurones of Drugs Influencing Monoaminergic and Gholinergic Transmission

  1966cited by this paper
• Experimentally produced tremor. Temporal factors in its development and disappearance in the monkey.

  1966cited by this paper
• Synaptic excitation in the corpus striatum inhibited by microelectrophoretically administered dopamine

  1966cited by this paper
• A comparative electromyographic study of the reactions to passive movement in parkinsonism and in normal subjects

  1966cited by this paper
• Cholinergic mechanisms in the caudate nucleus

  1966cited by this paper
• Reciprocal effects on alpha- and gamma-motoneurones of drugs influencing monoaminergic and cholinergic transmission.

  1966cited by this paper
• Changes in brain norepinephrine after decapitation.

  1966cited by this paper
• Topographic Brain Chemistry

  1966cited by this paper
• Striatal amines, experimental tremor and the effect of harmaline in the monkey.

  1966cited by this paper
• The red nucleus and its efferent nervous pathways in the monkey

  1966cited by this paper
• Ascending Monoamine Neurons to the Telencephalon and Diencephalon

  1966cited by this paper
• Dopamine (3-hydroxytyramine) and brain function.

  1966cited by this paper
• A quantitative study on the nigro-neostriatal dopamine neuron system in the rat.

  1966cited by this paper
• EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. IV. DISTRIBUTION OF MONOAMINE NERVE TERMINALS IN THE CENTRAL NERVOUS SYSTEM.

  1965cited by this paper
• [Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism].

  1965cited by this paper
• Role of the caudate nucleus in parkinsonian bradykinesia. (Effect of dopamine and of stereotaxic caudate lesions).

  1965cited by this paper
• The release of dopamine from the putamen

  1965cited by this paper
• Mapping out of catecholamine and 5-hydroxytryptamine neurons innervating the telencephalon and diencephalon.

  1965cited by this paper
• THE CORTICO-STRIATAL PROJECTION IN THE CAT.

  1965cited by this paper
• MODIFICATION BY DRUGS OF THE METABOLISM OF 3,4-DIHYDROXYPHENYLETHYLAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE BRAIN.

  1965cited by this paper
• Anesthesia and the responsiveness of individual neurons of the caudate nucleus of the cat to acetylcholine, norepinephrine and dopamine administered by microelectrophoresis.

  1965cited by this paper
• INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM.

  1965cited by this paper
• FURTHER EVIDENCE FOR THE PRESENCE OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS IN THE RAT.

  1965cited by this paper
• THE CORTICO-STRIATAL PROJECTION IN THE CAT.

  1965cited by this paper
• EFFERENT MUSCLE INNERVATION AND RIGIDITY.

  1964cited by this paper
• LESIONS OF THE SUBSTANTIA NIGRA IN THE RHESUS MONKEY. EFFERENT FIBER DEGENERATION AND BEHAVIORAL OBSERVATIONS.

  1964cited by this paper
• EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS.

  1964cited by this paper
• [Huntington's chorea].

  1964cited by this paper
• DYNAMIC RESPONSE OF CHEST WALL AND LUNG INJURIES IN RABBITS EXPOSED TO AIR SHOCK WAVES OF SHORT DURATION.

  1964cited by this paper
• THE EFFECT OF L-3, 4-DIHYDROXYPHENYLALANINE AND DL-5-HYDROXYTRYPTOPHAN ON RIGIDITY AND TREMOR INDUCED BY RESERPINE, CHLORPROMAZINE AND PHENOXYBENZAMINE.

  1964cited by this paper
• The neural mechanism of Parkinsonian tremor

  1964cited by this paper
• Effects of chlorpromazine, haloperidol and reserpine on the levels of phenolic acids in rabbit corpus striatum☆

  1964cited by this paper
• Some aspects of the pathophysiology of spasticity and rigidity

  1964cited by this paper
• THE ORGANIZATION OF CORTICO-STRIATE CONNEXIONSIN THE RABBIT.

  1963cited by this paper
• The negative symptoms of basal gangliar disease. A survey of 130 postencephalitic cases.

  1962cited by this paper
• The basal ganglia and their relation to disorders of movement

  1962cited by this paper
• The pathogenesis of Parkinson's disease: a new hypothesis.

  1962cited by this paper
• CATECHOLAMINE CONTENT OF SPINAL CORD

  1962cited by this paper
• Topical distribution of the striatal efferents in the monkey

  1962cited by this paper
• Changes in the 5-hydroxytryptamine content of rat, rabbit and human brain after death.

  1962cited by this paper
• The negative symptoms of basal gangliar disease. A survey of 130 postencephalitic cases.

  1962cited by this paper
• Correlative Anatomy of the Nervous System

  1962cited by this paper
• Supraspinal and drug modulation of the alpha motor system.

  1962cited by this paper
• [The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis].

  1962cited by this paper
• The pathology of Parkinson's syndrome: a critical review.

  1961cited by this paper
• Prolonged Stimulation of the Head of the Caudate Nucleus

  1961cited by this paper
• [Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome].

  1961cited by this paper
• [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

  1961cited by this paper
• The pathology of Parkinson's syndrome: a critical review.

  1961cited by this paper
• Occurrence and Localization of Catechol Amines in the Human Brain

  1961cited by this paper
• Stimulation of Caudate Nucleus: Behavioral Effects of Chemical and Electrical Excitation

  1961cited by this paper
• [On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6].

  1960cited by this paper

• Targeting the serotonergic system in the treatment of neurodegenerative diseases—emerging therapies and unmet challenges

  2025cites this paper
• Neurotrophin mimetics and tropomyosin kinase receptors: a futuristic pharmacological tool for Parkinson’s

  2023cites this paper
• Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease.

  2022cites this paper
• Recent advances in dopamine D2 receptor ligands in the treatment of neuropsychiatric disorders

  2022cites this paper
• Between Temperament and Psychopathology: Examples from Neuropharmacological Challenge Tests in Healthy Humans

  2021cites this paper
• Professor Oleh Hornykiewicz, MD (1926–2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man

  2020cites this paper
• Overview of Alzheimer's and Parkinson's diseases and the role of protein aggregation in these neurodegenerative diseases

  2020cites this paper
• Serotonin in Parkinson's disease

  2020cites this paper
• Serotonergic innervation of the striatum in a nonhuman primate model of Parkinson's disease.

  2020cites this paper
• Anxiety: An ignored aspect of Parkinson's disease lacking attention.

  2020cites this paper
• Classic animal models of Parkinson's disease: a historical perspective.

  2019cites this paper
• The Locus coeruleus in Parkinson’s disease - from basic research to new translational perspectives -

  2019cites this paper
• Mesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease

  2019cites this paper
• Early fine motor impairment and behavioral dysfunction in (Thy‐1)‐h[A30P] alpha‐synuclein mice

  2018cites this paper
• Modeling Serotonin’s Contributions to Basal Ganglia Dynamics in Parkinson’s Disease with Impulse Control Disorders

  2018cites this paper
• Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes

  2018cites this paper
• In Vivo Positron Emission Tomography of Extrastriatal Non-Dopaminergic Pathology in Parkinson Disease

  2018cites this paper
• Insights into the Cyclooxygenase Pathway in a Progressive Rat Model of Parkinson’s Disease Induced by Prostaglandin J2: Protection with Ibuprofen

  2018cites this paper
• Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets

  2018cites this paper
• Toxic effects of human and rodent variants of alpha‐synuclein in vivo

  2017cites this paper
• Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease

  2017cites this paper
• The reticular thalamic nucleus: revealing a novel phenotype of neurons and describing changes in a rat model of Parkinson’s disease.

  2017influential citation
• Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.

  2017cites this paper
• Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications

  2017cites this paper
• Brain dopamine neurone ‘damage’: methamphetamine users vs. Parkinson's disease – a critical assessment of the evidence

  2017cites this paper
• Resting-State Functional Connectivity of the Locus Coeruleus in Humans: In Comparison with the Ventral Tegmental Area/Substantia Nigra Pars Compacta and the Effects of Age.

  2016cites this paper
• Early Degeneration of Both Dopaminergic and Serotonergic Axons – A Common Mechanism in Parkinson’s Disease

  2016cites this paper
• New inorganic-based nanohybrids of layered zinc hydroxide/Parkinson’s disease drug and its chitosan biopolymer nanocarriers with controlled release rate

  2016cites this paper
• ACTUALIZACIÓN EN LA ENFERMEDAD DE PARKINSON

  2016cites this paper
• Motor symptoms in Parkinson's disease: A unified framework.

  2016cites this paper
• Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys

  2016cites this paper
• Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management

  2016cites this paper
• Correlation of Dopaminergic and Serotonergic Dysfunction in a Rat Model of Parkinson's Disease

  2015cites this paper
• The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein.

  2015cites this paper
• 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.

  2015cites this paper
• Vers l'imagerie in vivo de l'alpha-synucléine.

  2015cites this paper
• Nano-enabled delivery of diverse payloads across complex biological barriers.

  2015cites this paper
• Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions

  2015cites this paper
• Brain without Rictor: mTORC2 Signaling Regulates Central Dopamine Homeostasis

  2015cites this paper
• Monoamine Reuptake Inhibitors in Parkinson's Disease

  2015cites this paper
• Parkinson’s disease dementia: a neural networks perspective

  2015cites this paper
• Identifying the Basal Ganglia Network Model Markers for Medication-Induced Impulsivity in Parkinson's Disease Patients

  2015cites this paper
• Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system

  2015cites this paper
• A network model of basal ganglia for understanding the roles of dopamine and serotonin in reward-punishment-risk based decision making

  2015cites this paper
• The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.

  2015cites this paper
• Dopaminergic neuron destruction reduces hippocampal serotonin 1A receptor uptake of trans-[(18)F]Mefway.

  2014cites this paper
• Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.

  2014cites this paper
• Immunolocalization of human alpha-synuclein in the Thy1-aSyn ("Line 61") transgenic mouse line.

  2014cites this paper
• Parkinson-like neuronal loss and motor de fi cits but not microglia activation induced by prostaglandin J 2

  2014cites this paper
• Task force urges CT lung cancer screening for people at high risk

  2014cites this paper
• PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.

  2014cites this paper
• A computational model of altered gait patterns in parkinson's disease patients negotiating narrow doorways

  2014cites this paper
• Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by 18F-FP-(+)-DTBZ PET

  2013cites this paper
• The serotonergic system in motor and non-motor manifestations of Parkinson’s disease

  2013cites this paper
• Parameters impacting the outcome of cellreplacement therapy for Parkinson’s disease:A preclinical study

  2013cites this paper
• Characterization of Cognitive Deficits in Rats Overexpressing Human Alpha-Synuclein in the Ventral Tegmental Area and Medial Septum Using Recombinant Adeno-Associated Viral Vectors

  2013influential citation
• Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.

  2013cites this paper
• Optoelectronics and vibrational properties ofcarbidopa from quantum chemistry computations

  2013cites this paper
• l-DOPA and graft-induced dyskinesia: Different treatment, same story?

  2013cites this paper
• Circadian and sleep disorders in Parkinson's disease.

  2013cites this paper
• Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.

  2013cites this paper
• The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease

  2013cites this paper
• The contribution of functional neurosurgery to the understanding of the physiopathology of Parkinson’s disease

  2013cites this paper
• GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area

  2012cites this paper
• What can we expect from the serotonergic side of L-DOPA?

  2012cites this paper
• Noradrenergic Mechanisms in Parkinson’s Disease and L-DOPA-Induced Dyskinesia: Hypothesis and Evidences from Behavioural and Biochemical Studies

  2012cites this paper
• 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.

  2012cites this paper
• Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine.

  2012cites this paper
• Stem cells and Parkinson's disease

  2012cites this paper
• Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease

  2012cites this paper
• Experimental Models of l-DOPA-Induced Dyskinesia.

  2011cites this paper
• Activités normales et pathologiques du réseau hippocampique chez le rat : implication des systèmes monoaminergiques

  2011cites this paper
• Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus?

  2011cites this paper
• Dementia in Parkinsonism

  2011cites this paper
• Optimisation and mechanistic insights of dyskinesia in rodent models of Parkinson’s disease

  2011cites this paper
• Nondopaminergic treatments for Parkinson’s disease

  2011cites this paper
• The serotonergic system in Parkinson's disease.

  2011cites this paper
• Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

  2010cites this paper
• Serotonin and Parkinson's disease: On movement, mood, and madness

  2009cites this paper
• Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease.

  2009cites this paper
• Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic?

  2008cites this paper
• Levodopa: Past, Present, and Future

  2008cites this paper
• Imaging serotonin transporters using [123I]ADAM SPECT in a parkinsonian primate model.

  2008cites this paper
• Serotonin-dopamine interaction: electrophysiological evidence.

  2008cites this paper
• The Effects of Acute Tryptophan Depletion on Movement, Mood, and Cognition in Patients with Parkinson’s Disease and Healthy Older Persons

  2007influential citation
• 5-HYDROXYTRYPTAMINE MODULATION OF BRAIN DOPAMINE FUNCTION: IMPLICATIONS FOR THE TREATMENT OF PARKINSON'S DISEASE

  2006cites this paper
• Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?

  2006cites this paper
• Depression in Parkinson's disease – a review

  2006cites this paper
• The effect of depression on motor function and disease severity of Parkinson's disease.

  2006cites this paper
• EEG sleep patterns in Parkinsonian patients treated with Bromocryptine and L-Dopa: A comparative study

  2005cites this paper
• Post-mortem distribution of dopamine and homo-vanillic acid in human brain, variations related to age, and a review of the literature

  2005cites this paper
• Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine Levels in human basal ganglia

  2005cites this paper
• Pergolide therapy in parkinson's disease

  2004cites this paper
• Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity

  2004cites this paper
• Détérioration des voies dopaminergiques et altérations des fonctions cognitives et motrices

  2004cites this paper
• Pesticides and pesticide combinations on brain neurochemistry

  2004cites this paper
• Molecular Neurotoxicology of 6-Hydroxydopamine and Methamphetamine: Lessons Derived from Transgenic Models

  2003cites this paper
• Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.

  2003cites this paper
• Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?

  2003cites this paper
• Contributions of human brain biochemical studies to movement disorders.

  2002influential citation